These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28728494)

  • 1. The clinical significance of QT prolongation associated with tamoxifen: A review of the literature.
    Fung K; Imeson J; Cusano F
    J Oncol Pharm Pract; 2018 Oct; 24(7):525-530. PubMed ID: 28728494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitor-associated QT interval prolongation.
    Hunt K; Hughes CA; Hills-Nieminen C
    Ann Pharmacother; 2011 Dec; 45(12):1544-50. PubMed ID: 22128044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
    Khan Q; Ismail M; Haider I; Ali Z
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What clinicians should know about the QT interval.
    Al-Khatib SM; LaPointe NM; Kramer JM; Califf RM
    JAMA; 2003 Apr 23-30; 289(16):2120-7. PubMed ID: 12709470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.
    Beach SR; Celano CM; Sugrue AM; Adams C; Ackerman MJ; Noseworthy PA; Huffman JC
    Psychosomatics; 2018; 59(2):105-122. PubMed ID: 29275963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units.
    Khan Q; Ismail M; Haider I
    Postgrad Med; 2018 Nov; 130(8):660-665. PubMed ID: 30145917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azithromycin-induced proarrhythmia and cardiovascular death.
    Howard PA
    Ann Pharmacother; 2013 Nov; 47(11):1547-51. PubMed ID: 24285766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
    Khan Q; Ismail M; Khan S
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
    Briasoulis A; Agarwal V; Pierce WJ
    Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
    Das B; Rawat VS; Ramasubbu SK; Kumar B
    Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of high-risk use of QT-prolonging medications.
    Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approach to initiating QT-prolonging oncology drugs in the ambulatory setting.
    de Lemos ML; Kung C; Kletas V; Badry N; Kang I
    J Oncol Pharm Pract; 2019 Jan; 25(1):198-204. PubMed ID: 29298624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance and management of drug-related QT interval prolongation.
    Crouch MA; Limon L; Cassano AT
    Pharmacotherapy; 2003 Jul; 23(7):881-908. PubMed ID: 12885102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QTc prolongation, torsades de pointes, and psychotropic medications.
    Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
    Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Citalopram, QTc Prolongation, and Torsades de Pointes.
    Tampi RR; Balderas M; Carter KV; Tampi DJ; Moca M; Knudsen A; May J
    Psychosomatics; 2015; 56(1):36-43. PubMed ID: 25619672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes.
    Vieweg WV; Wood MA
    Psychosomatics; 2004; 45(5):371-7. PubMed ID: 15345781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
    Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
    J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial agents-associated with QT interval prolongation.
    Bril F; Gonzalez CD; Di Girolamo G
    Curr Drug Saf; 2010 Jan; 5(1):85-92. PubMed ID: 20210724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.